摘要
目的系统评价小牛血清去蛋白提取物(DCBE)治疗糖尿病并发症的有效性和安全性。方法计算机检索PubMed、EMbase、The Cochrane Library、CNKI、WanFang Data、CBM和VIP数据库,搜集DCBE治疗糖尿病并发症有效性和安全性的临床研究,检索时限均为建库至2020年7月8日。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.3软件进行Meta分析。结果共纳入69个研究。Meta分析结果显示:对于糖尿病神经病变,DCBE的总有效率优于空白对照、甲钴胺、维生素B_(12)、维生素B_(1)+维生素B_(12)、维生素B_(2)等;对于糖尿病足,DCBE的总有效率优于空白对照、敏感抗菌素和复方丹参注射液;对于糖尿病性视网膜病变,DCBE的总有效率优于空白对照。DCBE不良事件发生率为4.59%,但差异与各对照组无统计学意义。结论现有证据显示,DCBE治疗糖尿病神经病变、糖尿病足、糖尿病性干眼症、糖尿病性视网膜病变等均具有较好的有效性和安全性。受纳入研究数量和质量的限制,上述结论尚待更多高质量研究予以验证。
Objective To systematically review the efficacy and safety of deproteinized calf blood extractives(DCBE)for diabetic complications.Methods PubMed,EMbase,The Cochrane Library,CNKI,Wan Fang Data,CBM and VIP databases were electronically searched to collect studies on the efficacy and safety of DCBE for diabetic complications from inception to July 8;,2020.Two reviewers independently screened literature,extracted data and assessed the risk of bias of included studies;then,meta-analysis was performed using RevMan 5.3 software.Results A total of 69 studies were included.The results of meta-analysis showed that for diabetic neuropathy,the effect rate of DCBE was superior to control,mecobalamin,vitamin B_(12),vitamin B_(1)+vitamin B_(12),and vitamin B_(2),etc.For diabetic foot,the effect rate of DCBE was superior to control,sensitive antibiotic and compound salvia-miltiorrhiza injection.For diabetic retinopathy,the effect rate of DCBE was superior to control.The incidence of adverse events associated with DCBE was 4.59%.However,there was no significant difference with the control group.Conclusion Current evidence shows that DCBE has good efficacy and safety in diabetic neuropathy,diabetic foot,diabetic dry eye,diabetic retinopathy,and other diseases.Due to limited quality and quantity of the included studies,more high quality studies are required to verify the above conclusion.
作者
倪晓凤
杨春松
刘燕
张淼
张伶俐
NI Xiaofeng;YANG Chunsong;LIU Yan;ZHANG Miao;ZHANG Lingli(Department of Pharmacy,West China Second University Hospital Sichuan University,Chengdu 610041,P.R.China;Evidence-Based Pharmacy Center,West China Second University Hospital,Sichuan University,Chengdu 610041,P.R.China;Key Laboratory of Birth Defects and Related Diseases of Women and Children,Sichuan Vniversityy Ministry of Education,Chengdu 610041,P.R.China;West China School of Medicine,Sichuan University,Chengdu 610041,P.R.China;West China School of Pharmacy,Sichuan University,Chengdu 61004L P.R.China)
出处
《中国循证医学杂志》
CSCD
北大核心
2022年第2期202-210,共9页
Chinese Journal of Evidence-based Medicine
基金
国家自然科学基金项目(编号:71704123)
四川省科技计划项目(编号:2020YFS0035)。
